ProtaGene CGT
ProtaGene CGT is recorded as a service provider in 26 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 26 trials · Latest update first
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects (≥ 12 to < 18 Years of Age) with Severe or Moderately Severe Hemophilia B
Sponsor CSL Behring LLC
- Start (EU)
- Latest update
- Estimated end
A single arm, open label, clinical study of cryopreserved autologous CD34+ cells transduced with lentiviral vector containing human ARSA cDNA, for the treatment of early onset Metachromatic Leukodystrophy (MLD)
Sponsor Orchard Therapeutics (Europe) Limited
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available5 trial-level findings · Read insights
- The study was authorized and conducted at a single clinical site in Italy, and all treated subjects received OTL-200 in Italy.
- The planned sample size was based on feasibility in rare MLD rather than statistical considerations.
- Protocol version 6 expanded eligibility to permit enrollment and treatment of early-juvenile MLD at early symptomatic stages before rapid disease progression.
- Protocol version 7 specified arrangements for remote follow-up visits, including assessments by local healthcare professionals or teleconferencing.
- Protocol version 8 reduced required study long-term follow-up to a minimum of 5 years and allowed rollover to a 15-year post-treatment follow-up study.
These findings describe the trial, not the service provider’s performance or responsibility.
A Long-Term Follow-Up Study in Subjects with Severe Hemophilia A Who Received BMN 270, an Adeno-Associated Virus Vector–Mediated Gene Transfer of Human Factor VIII in a Prior BioMarin Clinical Trial
Sponsor Biomarin Pharmaceutical Inc.
- Start (EU)
- Latest update
- Estimated end
A prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate efficacy, safety, and tolerability of IMA203 versus investigator’s choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma (ACTengine® IMA203-301)
Sponsor Immatics US Inc.
- Start (EU)
- Latest update
- Estimated end
An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects with Hemophilia B
Sponsor CSL Behring LLC
- Start (EU)
- Latest update
- Estimated end
LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
A multicenter, non-therapeutic, interventional, long-term follow-up clinical trial to evaluate the safety of autologous PRAME-directed TCR T cell therapy IMA203 or IMA203CD8 in patients with previously treated, advanced and/or metastatic solid tumors
Sponsor Immatics US Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
Phase I/IIa, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-positive relapsed or refractory advanced solid tumors
Sponsor BioNTech Cell & Gene Therapies GmbH
- Start (EU)
- Latest update
- Estimated end
A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/CAS9-Based Coagulation Factor IX Gene Insertion Therapy in Participants with Hemophilia B
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured GLPG5101 (19CP02) in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma
Sponsor Lakefront Biotherapeutics
- Start (EU)
- Latest update
- Estimated end
A phase I/II open label, multicenter study evaluating the feasibility, safety and efficacy of point-of-care manufactured antiBCMA CAR T cells (GLPG5301; BCMACP03) in subjects with relapsed/refractory Multiple Myeloma (RRMM)
Sponsor Lakefront Biotherapeutics
- Start (EU)
- Latest update
- Estimated end
- Not reported
Sample Collection Study to Monitor the Risk of Malignancy Due to Insertional Oncogenesis in Early Onset Patients with Metachromatic Leukodystrophy Treated with OTL-200 in the Clinical Development Program
Sponsor Orchard Therapeutics (Europe) Limited
- Start (EU)
- Not reported
- Latest update
- Estimated end
Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector
Sponsor Genetix Biotherapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Longterm Follow-up of Subjects with Cerebral Adrenoleukodystrophy Who Were Treated with Lenti-D Drug Product
Sponsor Genetix Biotherapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A multi-center, randomized, active controlled clinical trial to evaluate the efficacy and safety of OTL-203 in subjects with mucopolysaccharidosis type I, Hurler syndrome (MPS-IH) compared to standard of care with allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Sponsor Orchard Therapeutics (Europe) Limited
- Start (EU)
- Latest update
- Estimated end
An open-label, single-arm, phase 1/2 first-in-human study to assess the safety and efficacy of autologous CD34+ cells transduced with a lentiviral vector encoding the human NCF1 gene (SGX-001) in paediatric and adult patients with chronic granulomatous disease caused by p47phox deficiency
Sponsor Somagenetix AG
- Start (EU)
- Not reported
- Latest update
- Estimated end
Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects with Severe or Moderately Severe Hemophilia B with Detectable Pretreatment AAV5 Neutralizing Antibodies.
Sponsor CSL Behring LLC
- Start (EU)
- Latest update
- Estimated end
Phase 1/2 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients with recurrent and/or refractory solid tumors (ACTengine® IMA203-101)
Sponsor Immatics US Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for ProtaGene CGT?
The 2026-10-09 snapshot links ProtaGene CGT to 26 distinct CTIS trials. Recorded services include Laboratory services, Insertion site analysis, Retroviral Insertion site analysis, Insertion Site Analysis (ISA), among 9 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for ProtaGene CGT?
The most frequently recorded therapeutic areas are Blood Disorders, Genetic and Congenital Disorders, Haematological Malignancies, Metabolic Disorders. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to ProtaGene CGT conducted?
The linked trials record locations in 19 countries, including Germany, Italy, Netherlands, France, Belgium. These are trial locations, not confirmed office locations or countries where ProtaGene CGT delivered services.
What can this page tell me about ProtaGene CGT's trial experience?
Browse 26 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under ProtaGene CGT. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- ProtaGene CGT GmbH
- Protagene Cgt GmbH